Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 May 27;36(8):1639-1651.
doi: 10.1681/ASN.0000000769.

Questions and Caveats in Antigen-Defined Membranous Nephropathy

Nicole K Andeen  1 , Vanderlene L Kung  1 , Rupali S Avasare  2 , Sean Barbour  3 , Megan Griffith  4   5 , Mei Lin Z Bissonnette  6 , Candice Roufosse  7   8
Affiliations
Review

Questions and Caveats in Antigen-Defined Membranous Nephropathy

Nicole K Andeen et al. J Am Soc Nephrol. .

Abstract

Remarkable progress has been made in the discovery of autoantigens in membranous nephropathy. With increasing testing for membranous antigens in daily practice, it is important to consider the varying strength of associations between certain antigens and underlying conditions. This review explores questions and caveats that arise when assessing results of membranous antigen testing. Specifically, we will discuss: ( 1 ) discrepancy between tissue antigen and clinical scenario, focusing on phospholipase A2 receptor; ( 2 ) one antigen≠one clinical condition, i.e ., the heterogeneity of membranous antigens seen in one clinical condition (such as in sarcoidosis), and conversely, heterogeneity of conditions associated with one antigen (such as for neural epidermal growth factor-like 1); ( 3 ) rare presence of multiple membranous-associated antigens in tissue or blood (such as with antiprotocadherin 7); and ( 4 ) lupus membranous nephritis-related antigens and their influence on diagnosis or treatment.

Keywords: clinical nephrology; glomerular disease; glomerular diseases; membranous nephropathy.

PubMed Disclaimer

Conflict of interest statement

Disclosure forms, as provided by each author, are available with the online version of the article at http://links.lww.com/JSN/F253.

References

    1. Beck LH Jr. Bonegio RG Lambeau G, et al. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med. 2009;361(1):11–21. doi: 10.1056/NEJMoa0810457 - DOI - PMC - PubMed
    1. Sethi S Beck LH Jr. Glassock RJ, et al. Mayo clinic consensus report on membranous nephropathy: proposal for a novel classification. Mayo Clin Proc. 2023;98(11):1671–1684. doi: 10.1016/j.mayocp.2023.08.006 - DOI - PubMed
    1. Bobart SA Han H Tehranian S, et al. Noninvasive diagnosis of PLA2R-associated membranous nephropathy: a validation study. Clin J Am Soc Nephrol. 2021;16(12):1833–1839. doi: 10.2215/CJN.05480421 - DOI - PMC - PubMed
    1. Kidney Disease Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group. KDIGO 2021 clinical practice guideline for the management of glomerular diseases. Kidney Int. 2021;100(4S):S1–S276. doi: 10.1016/j.kint.2021.05.021 - DOI - PubMed
    1. Bobart SA De Vriese AS Pawar AS, et al. Noninvasive diagnosis of primary membranous nephropathy using phospholipase A2 receptor antibodies. Kidney Int. 2019;95(2):429–438. doi: 10.1016/j.kint.2018.10.021 - DOI - PubMed

MeSH terms

LinkOut - more resources